321 related articles for article (PubMed ID: 32531271)
1. Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells.
Coles GL; Cristea S; Webber JT; Levin RS; Moss SM; He A; Sangodkar J; Hwang YC; Arand J; Drainas AP; Mooney NA; Demeter J; Spradlin JN; Mauch B; Le V; Shue YT; Ko JH; Lee MC; Kong C; Nomura DK; Ohlmeyer M; Swaney DL; Krogan NJ; Jackson PK; Narla G; Gordan JD; Shokat KM; Sage J
Cancer Cell; 2020 Jul; 38(1):129-143.e7. PubMed ID: 32531271
[TBL] [Abstract][Full Text] [Related]
2. Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism.
Patra KC; Kato Y; Mizukami Y; Widholz S; Boukhali M; Revenco I; Grossman EA; Ji F; Sadreyev RI; Liss AS; Screaton RA; Sakamoto K; Ryan DP; Mino-Kenudson M; Castillo CF; Nomura DK; Haas W; Bardeesy N
Nat Cell Biol; 2018 Jul; 20(7):811-822. PubMed ID: 29941929
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
4. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.
Yagishita S; Fujita Y; Kitazono S; Ko R; Nakadate Y; Sawada T; Kitamura Y; Shimoyama T; Maeda Y; Takahashi F; Takahashi K; Tamura T; Koizumi F
Mol Cancer Ther; 2015 Jun; 14(6):1414-23. PubMed ID: 25833836
[TBL] [Abstract][Full Text] [Related]
6. G Protein Alpha S Subunit Promotes Cell Proliferation of Renal Cell Carcinoma with Involvement of Protein Kinase A Signaling.
Zhang B; Sun N; Mu X; Zhi L; Zhai L; Jiang Y; Fu Z; Yao Z
DNA Cell Biol; 2017 Mar; 36(3):237-242. PubMed ID: 28051330
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer.
Yu J; Wang S; Zhao W; Duan J; Wang Z; Chen H; Tian Y; Wang D; Zhao J; An T; Bai H; Wu M; Wang J
Clin Cancer Res; 2018 May; 24(9):2148-2158. PubMed ID: 29437792
[No Abstract] [Full Text] [Related]
8. Oncogenic GNAS Uses PKA-Dependent and Independent Mechanisms to Induce Cell Proliferation in Human Pancreatic Ductal and Acinar Organoids.
Desai R; Huang L; Gonzalez RS; Muthuswamy SK
Mol Cancer Res; 2024 May; 22(5):440-451. PubMed ID: 38319286
[TBL] [Abstract][Full Text] [Related]
9. Gsα Controls Cortical Bone Quality by Regulating Osteoclast Differentiation via cAMP/PKA and β-Catenin Pathways.
Ramaswamy G; Kim H; Zhang D; Lounev V; Wu JY; Choi Y; Kaplan FS; Pignolo RJ; Shore EM
Sci Rep; 2017 Mar; 7():45140. PubMed ID: 28338087
[TBL] [Abstract][Full Text] [Related]
10. Elevated expression of GNAS promotes breast cancer cell proliferation and migration via the PI3K/AKT/Snail1/E-cadherin axis.
Jin X; Zhu L; Cui Z; Tang J; Xie M; Ren G
Clin Transl Oncol; 2019 Sep; 21(9):1207-1219. PubMed ID: 30767161
[TBL] [Abstract][Full Text] [Related]
11. [Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].
Zhu Y; Huang W; Wu Y; Jia L; Li Y; Chen R; Guo L; Chen Q
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):6-14. PubMed ID: 30674387
[TBL] [Abstract][Full Text] [Related]
12. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
13. Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy.
Wang Q; Zeng F; Sun Y; Qiu Q; Zhang J; Huang W; Huang J; Huang X; Guo L
Clin Cancer Res; 2018 Feb; 24(4):950-962. PubMed ID: 29208667
[No Abstract] [Full Text] [Related]
14. Impaired iloprost-induced platelet inhibition and phosphoproteome changes in patients with confirmed pseudohypoparathyroidism type Ia, linked to genetic mutations in GNAS.
Swieringa F; Solari FA; Pagel O; Beck F; Huang J; Feijge MAH; Jurk K; Körver-Keularts IMLW; Mattheij NJA; Faber J; Pohlenz J; Russo A; Stumpel CTRM; Schrander DE; Zieger B; van der Meijden PEJ; Zahedi RP; Sickmann A; Heemskerk JWM
Sci Rep; 2020 Jul; 10(1):11389. PubMed ID: 32647264
[TBL] [Abstract][Full Text] [Related]
15. GNAS knockdown suppresses osteogenic differentiation of mesenchymal stem cells via activation of Hippo signaling pathway.
An J; Li G; Zhang J; Zhou H; Jiang J; Wang X; Feng X; Wang S
J Cell Physiol; 2019 Dec; 234(12):22299-22310. PubMed ID: 31148202
[TBL] [Abstract][Full Text] [Related]
16. Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma.
Hao C; Liu G; Tian G
Ther Adv Respir Dis; 2019; 13():1753466619866097. PubMed ID: 31368411
[TBL] [Abstract][Full Text] [Related]
17. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid hormone(1-34) and its analogs differentially modulate osteoblastic
Ricarte FR; Le Henaff C; Kolupaeva VG; Gardella TJ; Partridge NC
J Biol Chem; 2018 Dec; 293(52):20200-20213. PubMed ID: 30377251
[TBL] [Abstract][Full Text] [Related]
19. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
20. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
